European Society of Anaesthesiology.

Dexrazoxane proved to be an effective and well-tolerated acute treatment with only one out of 54 assessable patients requiring surgical resection (1.8%).

No abstract

The kinetics of simultaneously injected 111In‐ and 51Cr‐labelled platelets have been assessed in 40 subjects, 13 of them thrombocytopenic. 4 platelet survival models were applied. The mean life‐time (MLT) of 51Cr‐platelets from non‐thrombocytopenic individuals was found to be slightly, but significantly, longer than that of 111In‐platelets by applying linear and exponential models for data fitting. The in vivo recovery (IVR) of 111In‐platelets was significantly higher than that of 51Cr‐platelets in this patient group when using all 4 models. In the group of thrombocytopenic patients no statistically significant differences in MLT or IVR were found between 111In‐ and 51Cr‐platelets. However, for each of the 11 51Cr‐labelled platelet suspensions with the shortest MLT, a longer MLT was observed in the corresponding 111In‐platelets, a finding probably related to antibody‐induced elution of 51Cr‐activity. The same mechanism might be responsible for an increasing 111In‐/51Cr‐recovery ratio in the early post‐injection period. The efficiency of platelet isolation from blood prior to labelling seemed to influence the IVR, inasmuch as the difference in IVR between 111In‐ and 51Cr‐platelets was eliminated in the group where the yield of 111In‐platelets surpassed that of the 51Cr‐platelets by more than 15 %.

No abstract